

SEQUENCE LISTING

<110> ENANTA PHARMACEUTICALS, INC.

WU, FRANK X.H.

NAKAJIMA, SUANNE

OR, YAT SUN

LU, ZHI-HUI

SUN, YING

MIAO, ZHENWEI

WANG, ZHE

<120> AZA-PEPTIDE MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS

<130> 50530-61558 WO

<140> PCT/US2004/015802

<141> 2004-05-19

<150> 10/613,206

<151> 2003-07-03

<160> 6

<170> PatentIn Ver. 3.2

<210> 1

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>

<221> MOD_RES

<222> (6)

<223> Abu

<220>

<223> see specification as filed for detailed description of preferred embodiments

<400> 1

Asp Glu Asp Glu Glu Xaa Ala Ser Lys

1

5

<210> 2

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<220>
<223> see specification as filed for detailed description of
preferred embodiments

<400> 2
Asp Glu Met Glu Glu Cys
1 5

<210> 3
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (3)
<223> Dif

<220>
<221> MOD_RES
<222> (4)
<223> Cha

<220>
<223> see specification as filed for detailed description of
preferred embodiments

<400> 3
Asp Glu Xaa Xaa Cys
1 5

<210> 4
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer

<400> 4
gctgcggcct gtcgagct

18

<210> 5
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer

<400> 5
caaggtcgtc tccgcatac

19

<210> 6
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Probe

<220>
<223> see specification as filed for detailed description of
preferred embodiments

<400> 6
cgaagctcca ggactgcacg atgct

25